Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2731281rdf:typepubmed:Citationlld:pubmed
pubmed-article:2731281lifeskim:mentionsumls-concept:C0022658lld:lifeskim
pubmed-article:2731281lifeskim:mentionsumls-concept:C0034152lld:lifeskim
pubmed-article:2731281lifeskim:mentionsumls-concept:C0032952lld:lifeskim
pubmed-article:2731281lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2731281lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:2731281pubmed:issue3lld:pubmed
pubmed-article:2731281pubmed:dateCreated1989-7-24lld:pubmed
pubmed-article:2731281pubmed:abstractTextThe authors hospitalized in 1976-1987 39 children with Schönlein-Henoch's purpura who on admission had a normal finding in urine. Of the above patients 28 were given prednisone already at the onset of hospitalization, to 11 prednisone was not administered. Patients with prednisone developed nephropathy in one instance (3.5%), patients without prednisone 6 times (54.5%) which is a significant difference. The average prednisone dose was 1.7 mg per kg body weight per day for an average period of 21 days. Usually for 6-10 days the same dose was administered and then it was gradually reduced.lld:pubmed
pubmed-article:2731281pubmed:languageslolld:pubmed
pubmed-article:2731281pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2731281pubmed:citationSubsetIMlld:pubmed
pubmed-article:2731281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2731281pubmed:statusMEDLINElld:pubmed
pubmed-article:2731281pubmed:monthMarlld:pubmed
pubmed-article:2731281pubmed:issn0069-2328lld:pubmed
pubmed-article:2731281pubmed:authorpubmed-author:GalandaVVlld:pubmed
pubmed-article:2731281pubmed:authorpubmed-author:BuchanecJJlld:pubmed
pubmed-article:2731281pubmed:authorpubmed-author:BelákováSSlld:pubmed
pubmed-article:2731281pubmed:authorpubmed-author:MinárikMMlld:pubmed
pubmed-article:2731281pubmed:authorpubmed-author:ZibolenMMlld:pubmed
pubmed-article:2731281pubmed:issnTypePrintlld:pubmed
pubmed-article:2731281pubmed:volume44lld:pubmed
pubmed-article:2731281pubmed:ownerNLMlld:pubmed
pubmed-article:2731281pubmed:authorsCompleteYlld:pubmed
pubmed-article:2731281pubmed:pagination145-6lld:pubmed
pubmed-article:2731281pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2731281pubmed:meshHeadingpubmed-meshheading:2731281-...lld:pubmed
pubmed-article:2731281pubmed:meshHeadingpubmed-meshheading:2731281-...lld:pubmed
pubmed-article:2731281pubmed:meshHeadingpubmed-meshheading:2731281-...lld:pubmed
pubmed-article:2731281pubmed:meshHeadingpubmed-meshheading:2731281-...lld:pubmed
pubmed-article:2731281pubmed:meshHeadingpubmed-meshheading:2731281-...lld:pubmed
pubmed-article:2731281pubmed:year1989lld:pubmed
pubmed-article:2731281pubmed:articleTitle[The effect of prednisone in the development of nephropathy in Schoenlein-Henoch purpura].lld:pubmed
pubmed-article:2731281pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2731281pubmed:publicationTypeEnglish Abstractlld:pubmed